139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC)
M. Ueno(Yokohama City University Medical Center), Richard S. Finn(University of California, Los Angeles), Changhoon Yoo(Ulsan College), Zhenggang Ren(Fudan University), Junji Furuse(Kyorin University Hospital), Robin Kate Kelley(University of California, San Francisco), Stephen L. Chan(Chinese University of Hong Kong), Julien Edeline(Centre Eugène Marquis), Heinz‐Josef Klümpen(Amsterdam University Medical Centers), Thomas Yau(University of Hong Kong), Chris Verslype(KU Leuven), Masato Ozaka(Japanese Foundation For Cancer Research), Mohamed Bouattour(Université Paris Cité), J.O. Park(Samsung Medical Center), Arndt Vogel(Medizinische Hochschule Hannover), Juan W. Valle(Cancer Research UK Manchester Institute), Liis Starkopf(Merck & Co., Inc., Rahway, NJ, USA (United States)), Usha Malhotra(Merck & Co., Inc., Rahway, NJ, USA (United States)), A.B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shukui Qin(Nanjing University of Chinese Medicine)
Cited by 3Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis